Dr. William J. Tester, MD

Dr. Tester practices at Jefferson Health Otolaryngology Head and Neck Surgery - HOPD in Philadelphia, Pennsylvania.

Dr. Tester's NPI, 1386613693, was assigned on March 17, 2006. Dr. Tester graduated from Hahnemann University College of Medicine in 1972. Dr. Tester holds Pennsylvania license MD021791E.

Dr. Tester's primary practice is Jefferson Health Otolaryngology Head and Neck Surgery - HOPD, at 925 Chestnut Street, Philadelphia, PA 19107.

Dr. Tester's primary practice is Jefferson Health Otolaryngology Head and Neck Surgery - HOPD in Philadelphia, Pennsylvania. Dr. Tester is also affiliated with Thomas Jefferson University Hospital. The medical group on file is Jefferson University Physicians. Dmand AI also links Dr. Tester to 1 more hospital, 1 group practice or clinic, 1 hospital outpatient department and 1 medical group, each named with a free account. Dr. Tester's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tester practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tester's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tester is licensed in Pennsylvania.

CMS data shows 303 Medicare services from Dr. Tester across 5 procedure codes in 2024, for 128 Medicare patients. Medicare paid $28,368 for them.

CMS counts 128 Medicare patients who saw Dr. Tester in 2024. The largest group is 65 to 74, with 67 patients. 75% of them have cancer, and 75% have high blood pressure. 18% are also on Medicaid. Their average risk score is 2.18, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tester's median patient age at 71, with 24% women.

In 2024, Dr. Tester wrote 564 Medicare Part D claims for 66 patients. 69% of them were for generic drugs. CMS names the drug for 430 of them, across 13 drugs with 11 or more claims each, at $1,680,519 in total drug cost. In 2023, CMS named 442 claims across 15 drugs.

Dr. Tester accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tester as offering telehealth.

Dmand AI links 23 papers to Dr. Tester, published from 2006 to 2024. 2013 was the busiest year, with 3. The most frequent topics are Urinary Bladder Neoplasms, Biomarkers, Tumor and Antigens, Neoplasm. Dr. Tester has published most often in Can J Urol. Dr. Tester's most frequent co-authors are Jongoh Kim, MD, John Charles Leighton, MD and Patrick Johnston Mille, MD.

Dmand AI links Dr. Tester to 4 clinical trials, 3 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Ureteral Neoplasms. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 23 general payments to Dr. Tester from 11 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 54% of the total. Janssen Pharmaceuticals, Inc paid the most, $4,312.

Dr. Tester graduated from Hahnemann University College of Medicine in 1972.